Tahoe Therapeutics, based in Palo Alto and formerly known as Vevo Therapeutics, is a TechBio company building the data foundation for AI models of the human cell. The company's conviction is that the bottleneck in AI-driven biology is not model architecture but the scale and quality of biological measurement data. To address this, Tahoe generates enormous single-cell datasets that capture how cells respond to thousands of drug perturbations across many patient contexts.
At the center of Tahoe's approach is its Mosaic platform, a high-throughput experimental system that pools many cell lines and exposes them to large panels of compounds, then reads out the molecular consequences at single-cell resolution. This perturbative approach measures not just what cells look like, but how they change in response to interventions, which is precisely the kind of causal signal needed to train predictive models of drug response. In early 2025 the company released Tahoe-100M, described as the world's first gigascale perturbative single-cell dataset, which was downloaded close to 100,000 times and became a widely used resource for the machine-learning and computational-biology community.
The company's goal is to map a million drug-patient interactions and generate roughly a billion single-cell datapoints, building toward AI virtual-cell models that can predict how a given drug will affect a given patient's cells before any clinical exposure. This positions Tahoe at the intersection of lab automation, single-cell genomics, and foundation-model training, supplying the perturbation data that downstream therapeutic and discovery efforts depend on.
In August 2025 Tahoe raised a $30 million Series A led by Amplify Partners, with participation from Databricks Ventures, Wing Venture Capital, General Catalyst, Civilization Ventures, Conviction, Mubadala Capital Ventures, Overlap Holdings, and AIX Ventures, bringing total funding to about $42 million at a $120 million valuation. Earlier, as Vevo Therapeutics, the company had closed an oversubscribed seed round co-led by Wing Venture Capital and General Catalyst. The fresh capital funds dramatic expansion of single-cell data production to power the next generation of AI cell models.